LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry
• Public Health

Background:

• Coronary artery disease (CAD) management traditionally targets low-density lipoprotein cholesterol (LDL-C).
• LDL-C, while a key risk factor for atherosclerosis, has limitations as a sole predictor of CAD.
• Emerging evidence highlights non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein-B (Apo-B) as superior risk predictors.

Purpose of the Study:

• To review the reliability and efficacy of non-HDL-C in assessing CAD risk.
• To advocate for the integration of non-HDL-C into routine lipid panels for improved CAD assessment.
• To address the practical considerations of lipid testing in developing countries like India.

Main Methods:

• Review of existing scientific literature and clinical evidence on non-HDL-C and Apo-B.
• Comparative analysis of LDL-C, non-HDL-C, and Apo-B as predictors of CAD.
• Evaluation of the clinical utility and cost-effectiveness of non-HDL-C testing.

Main Results:

• Non-HDL-C and Apo-B are substantiated as more reliable predictors of CAD risk than LDL-C.
• Non-HDL-C is proposed as a more realistic primary therapeutic target and suitable for initial screening.
• Non-HDL-C estimation in a non-fasting state offers patient and clinician convenience, avoiding additional costs associated with Apo-B.

Conclusions:

• Non-HDL-C demonstrates significant reliability and efficacy in assessing CAD risk.
• Incorporating non-HDL-C into routine lipid panels is recommended for enhanced CAD risk assessment.
• Non-HDL-C provides a practical and cost-effective alternative for lipid screening, especially in resource-limited settings.